secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001104659-24-125265
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax subsidiary agrees to sell Czech manufacturing campus to Novo Nordisk subsidiary for $200M
--------------------------------------------------------------------------------

- Total purchase price $200M; $10M credit from September 2024 and $10M escrow released 12 months post-closing.
- Closing conditioned on Czech drug regulator modifying Novavax CZ's manufacturing authorization to reduce scope.
- Novavax CZ continues operations; purchaser reimburses operating costs up to $3.5M per month until closing.
- Customary indemnification; termination right if condition not satisfied within 4 months of signing.
- Transaction involves transfer of land, equipment, contracts, and employees at Bohumil, Jevany facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924125265/0001104659-24-125265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924125265/tm2430032d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-125265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer